Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3E5EG5
Fri, 13.10.2023
PAION AG
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Ad-hoc Announcement
Inside information according to Article 17 EU Market Abuse Regulation (MAR)
PAION AG announces fully underwritten rights issue with target gross pro [ … ]
Thu, 28.09.2023
PAION AG
PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE MUNDIPHARMA IN JAPAN
Aachen, Germany, 28. September 2023 – PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and hospital sedation, anesthesia and critical [ … ]
Thu, 31.08.2023
PAION AG
PAION receives UK MHRA approval of Byfavo® (remimazolam) for the induction and maintenance of general anesthesia in adults
Aachen (Germany), 31 August 2023 - PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, a [ … ]
Wed, 30.08.2023
PAION AG
PAION AG reports financial results for the First Half-Year 2023
Byfavo® approval by European Commission for general anesthesia in April 2023, launch followed in August 2023
Hana Pharm received approval for Byfavo® in general anesthesia in the Philippines in July 2023
TTY Biopharm filed in general anesthesia in Taiwan in March 2023
Combined [ … ]
Tue, 22.08.2023
PAION AG
PAION launches Byfavo® (remimazolam) in the first European country for General Anesthesia
Byfavo® is now commercially available in the Netherlands for the use in general anesthesia
PAION will launch Byfavo® with its distribution partners in a staggered manner by country
PAION estimates that approximately 30 million surgeries are performed un [ … ]
Mon, 14.08.2023
PAION AG
Tilmann Bur succeeds Gregor Siebert as CEO of PAION AG
Tilmann Bur appointed to the Management Board as CEO effective 01 September 2023
As planned, Gregor Siebert as interim CEO will leave the Management Board on 30 September 2023 and will then continue to use his experience gained strategically as a member of the Supervisory Board of PAION
[ … ]
Mon, 17.07.2023
PAION AG
PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR BYFAVO IN GENERAL ANESTHESIA IN THE PHILIPPINES
ByfavoTM launch in the Philippines expected in the fourth quarter of 2023
Hana Pharm's ByfavoTM sales increased by 260% in South Korea in 2022
Aachen, Germany, 17. July 2023 – PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standa [ … ]
Mon, 17.07.2023
PAION AG
PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR BYFAVO IN GENERAL ANESTHESIA IN THE PHILIPPINES
ByfavoTM launch in the Philippines expected in the fourth quarter of 2023
Hana Pharm's ByfavoTM sales increased by 260% in South Korea in 2022
Aachen, Germany, 17. July 2023 – PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standa [ … ]
Wed, 12.07.2023
PAION AG
PAION AG SUCCESSFULLY HOLDS ITS ANNUAL GENERAL MEETING 2023
At the AGM presence of the share capital at around 16%
Dr. Karin Louise Dorrepaal appointed as member of the Supervisory Board for a further term of office
Attorney-at-law Dr. Mirko Sickinger newly elected to the Supervisory Board
Aachen, 12 July 2023 – PAION AG (ISIN DE000A3E5EG5; Fra [ … ]
Wed, 12.07.2023
PAION AG
PAION AG SUCCESSFULLY HOLDS ITS ANNUAL GENERAL MEETING 2023
At the AGM presence of the share capital at around 16%
Dr. Karin Louise Dorrepaal appointed as member of the Supervisory Board for a further term of office
Attorney-at-law Dr. Mirko Sickinger newly elected to the Supervisory Board
Aachen, 12 July 2023 – PAION AG (ISIN DE000A3E5EG5; Fra [ … ]